A Study to Evaluate the Effect of Different Meal Types on the Pharmacokinetics of DBPR108 in Healthy Subjects

Healthy Subjects Clinical Trial

Official title:

An Open-label, Randomized, Three-period, Crossover, Single-dose Study to Evaluate the Effect of a Low-fat Meal and a Standard Meal on the Pharmacokinetics of DBPR108 in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05150626
• Other study ID #: HA1118-013
• Status: Completed
• Phase: Phase 1
• Start date: May 29, 2022
• Est. completion date: July 14, 2022

Study information

• Verified date: April 2023
• Source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, randomized, three-period, crossover, single-dose study to evaluate the effects of a low-fat meal and a standard meal on the pharmacokinetics of DBPR108 and the safety and tolerability of DBPR108 under different fed states in healthy adult subjects.

Description:

The objective of the study is to evaluate the effect of different meal types on the pharmacokinetics of DBPR108, a potent dipeptidylpeptidase-4 inhibitor. In this open-label, randomized, three-period, crossover study, healthy subjects will receive a single dose of DBPR108 100 mg under fasted conditions and following a low-fat meal or a standard meal. Twenty-one healthy subjects will be randomized 1:1:1 to Sequence A, Sequence B, or Sequence C. This study will consist of a screening and baseline period, a treatment period, and a follow-up period. Blood samples for pharmacokinetic assessments will be taken pre-dose and up to 48 h post-dose.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: July 14, 2022
• Est. primary completion date: June 7, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Subjects fully understand and voluntarily participate in this study and sign informed consent;

2. Healthy male and/or female subjects between the ages of 18 and 45 years (inclusive);

3. Body Mass Index (BMI) of 18 to 28 kg/m2 (inclusive), body weight for male =50.0 kg and for female=45.0 kg;

4. Subjects (including their partners) are willing to use effective contraceptives from screening to the 6 months after the last dose administration;

5. Subjects judged to be in good health by the investigator, based on the physical examination, vital signs examination, 12-lead electrocardiogram (ECG) examination and laboratory examination etc;

Exclusion Criteria:

1. History of allergic conditions, or allergic to any ingredients of DBPR108;

2. History of severe diseases, such as cardiovascular, respiratory, liver, gastrointestinal, endocrine, hematological, psychiatric/neurological systems diseases within 1 year prior to screening;

3. History of hypoglycemia or abnormal blood glucose at screening: fasting blood glucose <70 mg/dL (3.9 mmol/L) or >110 mg/dL (6.1 mmol/L);

4. Subjects who have previously undergone surgery (e.g., subtotal gastrectomy) that may affect the absorption, distribution, metabolism, or excretion of the drug, or who have a scheduled surgery during the study period;

5. History of drug abuse, or urine drug screening is positive at screening;

6. Smoking more than 5 cigarettes per day within 3 months prior to screening, or who cannot stop using nicotine-containing products during the study period;

7. Regular alcohol consumption exceeding 15 g/day(female) or 25 g/day(male) (15 g ˜ 450 mL beer, or 50 mL hard liquor, or 150 mL wine) within the 3 months prior to screening, or taking any product containing alcohol within 48 h before dosing, or alcohol test is positive;

8. Blood donation (or blood loss) =400 mL, or receiving blood product transfusion within 3 months prior to screening;

9. Consumption of grapefruit juice, methylxanthine-rich food or beverage (such as coffee, tea, cola, chocolate, energy drinks), or those who have had strenuous exercise, or have other factors affecting drug absorption, distribution, metabolism, excretion, within 48 h before the administration;

10. Use of any prescription drug, over-the-counter drug (except acetaminophen and some nasal sprays), or herbal medicine within 2 weeks prior to screening;

11. Have special dietary requirements and cannot consume the study meals;

12. Subject with hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody or Treponema pallidum antibody positive;

13. Enrolled in any other clinical trial within 3 months before screening (whichever is administrated);

14. Have been vaccinated within 4 weeks prior to screening or who have a scheduled vaccination during the study period;

15. Pregnant/lactating woman, or who has a positive blood pregnancy test at screening;

16. Not suitable for this study as decided by the investigator due to other reasons.

Related Conditions & MeSH terms

• Healthy Subjects

Intervention

Drug:
• DBPR108 tablets
Drug: DBPR108, tablets, oral

Locations

Country	Name	City	State
China	First Affiliated Hospital of Soochow University	Suzhou

Sponsors (1)

Lead Sponsor	Collaborator
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peak plasma concentration (Cmax) of DBPR108		Predose and at prespecified time point after DBPR108 dosing on Day 1, Day 5 and Day 9.
Primary	Area under the plasma concentration versus time curve from time zero to the time of last measurable concentration (AUClast) of DBPR108		Predose and at prespecified time point after DBPR108 dosing on Day 1, Day 5 and Day 9.
Primary	Area under the plasma concentration versus time curve from time zero to infinity (AUCinf) of DBPR108		Predose and at prespecified time point after DBPR108 dosing on Day 1, Day 5 and Day 9.
Secondary	Time to achieve maximum plasma concentration (Tmax) of DBPR108		Predose and at prespecified time point after DBPR108 dosing on Day 1, Day 5 and Day 9.
Secondary	Half-life (t1/2) of DBPR108		Predose and at prespecified time point after DBPR108 dosing on Day 1, Day 5 and Day 9.
Secondary	Apparent clearance (CL/F) of DBPR108		Predose and at prespecified time point after DBPR108 dosing on Day 1, Day 5 and Day 9.
Secondary	Apparent volume of Distribution (Vz/F) of DBPR108		Predose and at prespecified time point after DBPR108 dosing on Day 1, Day 5 and Day 9.
Secondary	Number of subjects with treatment-related adverse events as assessed by CTCAE v5.0		Day 1 to Day 14